GENERINI, SERGIO
 Distribuzione geografica
Continente #
NA - Nord America 2.244
EU - Europa 1.266
AS - Asia 269
AF - Africa 3
OC - Oceania 2
Totale 3.784
Nazione #
US - Stati Uniti d'America 2.239
PL - Polonia 414
IE - Irlanda 229
SE - Svezia 215
IT - Italia 124
HK - Hong Kong 119
UA - Ucraina 81
CN - Cina 59
FI - Finlandia 56
DE - Germania 54
GB - Regno Unito 37
TR - Turchia 37
CH - Svizzera 19
JO - Giordania 17
SG - Singapore 17
RU - Federazione Russa 13
AT - Austria 11
VN - Vietnam 8
IN - India 6
KR - Corea 6
CA - Canada 5
AL - Albania 3
FR - Francia 3
SC - Seychelles 3
BG - Bulgaria 2
ES - Italia 2
AU - Australia 1
BE - Belgio 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
RO - Romania 1
Totale 3.784
Città #
Warsaw 414
Fairfield 344
Chandler 295
Dublin 229
Ashburn 190
Woodbridge 144
Jacksonville 130
Cambridge 129
Seattle 123
Wilmington 120
Houston 86
Hong Kong 68
Princeton 61
Buffalo 58
Medford 48
Boardman 44
Ann Arbor 41
Altamura 40
Izmir 37
Lawrence 35
Beijing 26
Boston 25
Shanghai 23
Bern 18
New York 18
San Diego 17
Florence 13
Kent 13
Singapore 11
Vienna 11
Dong Ket 8
West Jordan 8
Norwalk 6
Los Angeles 5
Milan 5
Salerno 5
Seoul 5
Andover 4
Greenwich 4
Hillsboro 4
Auburn Hills 3
Falls Church 3
Frankfurt Am Main 3
Parma 3
Pune 3
Rome 3
San Mateo 3
Barcelona 2
Bremen 2
Caserta 2
Dearborn 2
Hounslow 2
Langen 2
Montréal 2
Phoenix 2
Segrate 2
Tappahannock 2
Toronto 2
Turin 2
Verona 2
Ahmedabad 1
Auckland 1
Brooklyn 1
Brussels 1
Bryant 1
Cedar Knolls 1
Costa Mesa 1
Drobeta-Turnu Severin 1
Fucecchio 1
Grosseto 1
Hebei 1
Helsinki 1
Islington 1
Kunming 1
Lachine 1
Lake Zurich 1
Leawood 1
Lissone 1
Liverpool 1
London 1
Lucca 1
Lurate Caccivio 1
Manchester 1
Monmouth Junction 1
Moscow 1
Palermo 1
Philadelphia 1
Pine Bush 1
Portland 1
Redwood City 1
Saint Petersburg 1
Shenyang 1
Southwark 1
Sydney 1
Trumbull 1
Vaglia 1
Zurich 1
Totale 2.949
Nome #
Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis 218
[Peripheral nervous system in limited systemic sclerosis]. 208
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn). 192
Activin, a grape seed derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. 97
Estrogens and neuropeptides in Raynaud's phenomenon. 96
Damage of cutaneous peripheral nervous system evolves differently according to the disease phase and subset of systemic sclerosis 94
Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. 90
Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers 87
DRESS syndrome in a patient with chronic hepatic encephalopathy. 86
Evidence for the prevention of enthesitis in HLA-B27/hβ(2)m transgenic rats treated with a monoclonal antibody against TNF-α. 85
Oxidative stress in Systemic Sclerosis. 84
High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. 84
Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. 84
Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. 82
Screening of distress among hospitalized patients in a department of internal medicine. 79
Exercise Doppler echocardiography identifies preclinic asymptomatic pulmonary hypertension in systemic sclerosis. 78
Increased circulating levels of tissue kallikrein in systemic sclerosis correlate with microvascular involvement 78
Somatostatin-induced modulation of inflammation in experimental arthritis 77
Diene-conjugates and antibodies against oxidized low-density lipoproteins in systemic sclerosis. 72
Longitudinal ultrasound and clinical follow-up of Baker's cysts injection with steroids in knee osteoarthritis. 71
NGF, a useful tool in the treatment of chronic vasculitic ulcers in rheumatoid arthritis. 70
Circulating levels of Nepsilon-(carboxymethyl)lysine are increased in systemic sclerosis. 68
Are Angiotensin Converting Enzyme and von Willebrand factor circulating levels useful surrogate parameters to monitor disease activity in Kawasaki disease? 65
Discrepant expression of neprilysin on fibroblasts in diffuse systemic sclerosis. 63
Evidence for the prevention of enthesitis in HLA-B27/hβ(2) m transgenic rats treated with a monoclonal antibody against TNF-α 60
Bcl-2, p53 and c-myc expression in juvenile dermatomyositis. 58
Reduction of bcl-2 in T cells during immunosuppressive therapy in patients with severe juvenile onset systemic lupus erythematosus. 58
Current Treatment Options in Raynaud's Phenomenon. 58
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. 57
Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis 57
Urokinase-type plasminogen activator is the main plasminogen activator produced by synoviocytes of osteoarthritis and rheumatoid arthitis 56
Raynaud's phenomenon and vascular disease in systemic sclerosis. 56
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. 56
Increased circulating nerve growth factor is directly correlated with disease activity in juvenile chronic arthritis. 54
Vasculitides secondary to systemic diseases. 54
Postural and kinesiologic evaluation in patients with early ankylosing spondylitis. 54
Melatonin is a safe and effective treatment for chronic pulmonary and extrapulmonary sarciodosis 52
NEPRILYSIN LEVELS IN PLASMA AND SYNOVIAL FLUID OF JUVENILE IDIOPATHIC ARTHRITIS PATIENTS. RHEUMATOL INT. 2005 JUN;25(5):336-40. EPUB 2004 MAR 3. 51
TNFalpha blockade prevents the development of inflammatory bowel disease in HLA-B27 transgenic rats 51
Clinical and laboratory features and disease outcome of kawasaki disease: the analysis of our experience and literature review. 50
Neuropeptides and steroid hormones in arthritis. 49
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). 49
Evidence of immune activation against oxidized lipoproteins in inactive phases of juvenile chronic arthritis. 49
The loss of endothelium dependent vascular tone control in systemic sclerosis. 47
Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment. 44
Evidence for hyaluronan production in the air pouch model in rats. 42
Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. 41
A Sonographic (Us) Evaluation Of Ligaments Of Sacroiliac Joint In Healthy Subjects 37
The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. 28
Therapy of spondylarthropathy in inflammatory bowel disease. 27
Iliopsoas bursitis in rheumatoid arthritis. 27
Peripheral nervous system involvement in systemic sclerosis: the median nerve as target structure. 27
Raynaud's phenomenon and systemic sclerosis. 25
Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease activity and reduced angiotensin converting enzyme levels. 24
Systemic sclerosis. A clinical overview. 23
Statin-induced, immune-mediated injury with simultaneous targeting of skeletal muscle, skin and liver 23
The nervous system in systemic sclerosis (scleroderma). Clinical features and pathogenetic mechanisms. 22
New approaches to Raynaud's phenomenon [corrected]. 21
Erratum: "The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn) (Clinical and Experimental Rheumatol (2005) vol. 23 (5) (671-677)) 12
Totale 3.807
Categoria #
all - tutte 11.387
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.387


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020794 59 66 30 69 85 97 87 100 80 40 64 17
2020/2021488 46 37 40 45 22 66 13 41 41 65 29 43
2021/2022354 10 37 10 11 8 15 13 15 15 13 92 115
2022/20231.019 105 153 39 102 86 188 124 53 96 15 32 26
2023/2024387 14 39 63 18 34 67 15 85 2 16 25 9
2024/202525 25 0 0 0 0 0 0 0 0 0 0 0
Totale 3.807